Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Announces Execution of Mixed Investment Agreement for the Three Mexico Projects7.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that, further to its press release dated June 8, 2026, it has reached another important milestone in the development of its three renewable energy projects selected under Mexico's Comisión Federal de Electricidad ("CFE") Mixed Development Program (the "Mixed Program"). On July 3, 2026, Polaris, through its Mexican project structure, executed the Mixed Investment Agreement (Contrato de Inversión Mixta or "CIM") with the fiduciary trustee, Banca Mifel, S.A., Institucion de Banca Multiple, Grupo Financiero Mifel, acting on behalf of CFE. The CIM establishes the contractual 30-year framework governing the joint participation of Polaris and CFE in the development, financing, construction, ownership and operation of the three selected projects, including the applicable governance, economic and corporate arrangements. The CIM includes the key information a
Oxford University Press Comes to Simply Piano7.7.2026 10:00:00 CEST | Press release
Content from OUP's acclaimed piano method is now available to millions of Simply Piano learners worldwide NEW YORK, NY / ACCESS Newswire / July 7, 2026 / Simply, the leading digital platform for creative hobbies, today announced an agreement to bring content from Oxford University Press' (OUP) piano method to Simply Piano. This expands Simply Piano's offering and marks a step forward in its mission to make the pursuit of creative hobbies simple and fun for all. Simply Piano users around the world will gain access to an expanded library of high-quality, curated sheet music spanning OUP's works including Piano Time and Tunes for Ten Fingers, all within the app's interactive learning environment. The integration expands Simply Piano's sheet music library across genres, complementing its step-by-step courses and real-time feedback tools. "Access to songs people love is one of the strongest drivers of learning," said Yuval Kaminka, CEO & co-founder of Simply. "Working with OUP allows us to
AM Technical Solutions Acquires Sequence, Inc., Expanding Life Sciences Engineering and Commissioning, Qualification, and Validation (CQV) Capabilities7.7.2026 07:00:00 CEST | Press release
KILDARE, IRELAND / ACCESS Newswire / July 7, 2026 / AM Technical Solutions (AM), a global architecture, engineering, construction, and commissioning firm specializing in high-technology markets, announces the acquisition of Sequence, Inc., a leading engineering firm specializing in Process Design, Commissioning, Qualification, and Validation (CQV) solutions for life sciences and related high-tech industries. Sequence, headquartered in Morrisville, North Carolina, brings deep expertise in CQV, Computer System Validation (CSV), IT/OT integration, operational readiness, and life sciences engineering excellence. Their cross-functional approach to process engineering and facility startup has earned them a strong track record accelerating time to market for pharmaceutical and biopharmaceutical clients across the full project lifecycle -- from conceptual design through licensure and commercial operations. This acquisition deepens AM's existing Engineering and CQV capabilities with proven team
Crossmint Secures Payment Institution and MiCA Authorization, Completing a Full-Stack EU Regulatory Stack for Stablecoin Payments3.7.2026 21:00:00 CEST | Press release
With Authorization as a Crypto-Asset Service Provider Under MiCA and Payment Institution Under PSD2, Crossmint Now Operates Under Both of the EU's Core Frameworks for Stablecoin Infrastructure, Giving Enterprise Fintechs One Regulated Provider to Hold Stablecoins and Move Them as Payments MADRID, ES / ACCESS Newswire / July 3, 2026 / Crossmint has been authorized as a Payment Institution (PI) by the Bank of Spain under the EU's Payment Services Directive (PSD2). Earlier this year, Crossmint received MiCA class 2 authorization from Spain's CNMV, establishing complete authorization to operate as a crypto-asset service provider across the EU. After completing the required conditions, Crossmint has now successfully been fully registered as a CASP with CNMV, which allows passporting across all 27 EU member states. PSD2 authorization is the natural expansion of that compliance footprint, enabling stablecoins to be used as a means of payment under EU payments law. "Crossmint's mission is to b
Polaris Renewable Energy Announces Q2 2026 Investor Call Details3.7.2026 19:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 3, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2026 Earnings Results on Thursday, July 30th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 503447 or URL: https://www.webcaster5.com/Webcast/Page/2773/53517 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53517 International (toll-free): 1 919-882-2331, Passcode: 53517 Encore Replay Expiration Date: August 13, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom